Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2025-06-13 DOI:10.1080/1750743X.2025.2518913

Michelle Bradbury, Adam Gabara, Gregory R Pond, Brandon M Meyers, Adi Kartolo

{"title":"Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience.","authors":"Michelle Bradbury, Adam Gabara, Gregory R Pond, Brandon M Meyers, Adi Kartolo","doi":"10.1080/1750743X.2025.2518913","DOIUrl":null,"url":null,"abstract":"Background: Treatment of platinum-refractory recurrent and metastatic head and neck squamous cell carcinoma (r/mHNSCC) involves immune-checkpoint inhibitors. Time toxicity (TT) is an emerging metric with implications for patient quality of life and decision-making. We sought to evaluate TT associated with nivolumab in these patients.Methods: This is a retrospective single-institution review of patients with platinum-refractory r/mHNSCC seen at an academic cancer center between 1 January 2018 to 31 December 2022 in Ontario, Canada. Primary outcome is TT, defined as any number of days spent undergoing cancer-related activities.Results: Of 56 patients evaluated, median age was 63 years (33-85) and 84% were male. Median overall survival (OS) and grade 3 immune-toxicities were 7.6 months and 6.2%, respectively. Median TT was 24 days (1-109), accounting for 7.6% of OS. TT accounted for 14.9% of OS in poor responders. TT accounted for only 4-6% for patients who survived more than a year.Conclusions: Our study provides an important and underexplored patient-centered metric in TT, especially in the context of incurable HNSCC with abysmal survival outcome. Our findings suggest that TT varies significantly between responders and non-responders. Duration of TT should be discussed with patients in shared decision-making when discussing palliative nivolumab.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2518913","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Treatment of platinum-refractory recurrent and metastatic head and neck squamous cell carcinoma (r/mHNSCC) involves immune-checkpoint inhibitors. Time toxicity (TT) is an emerging metric with implications for patient quality of life and decision-making. We sought to evaluate TT associated with nivolumab in these patients.

Methods: This is a retrospective single-institution review of patients with platinum-refractory r/mHNSCC seen at an academic cancer center between 1 January 2018 to 31 December 2022 in Ontario, Canada. Primary outcome is TT, defined as any number of days spent undergoing cancer-related activities.

Results: Of 56 patients evaluated, median age was 63 years (33-85) and 84% were male. Median overall survival (OS) and grade 3 immune-toxicities were 7.6 months and 6.2%, respectively. Median TT was 24 days (1-109), accounting for 7.6% of OS. TT accounted for 14.9% of OS in poor responders. TT accounted for only 4-6% for patients who survived more than a year.

Conclusions: Our study provides an important and underexplored patient-centered metric in TT, especially in the context of incurable HNSCC with abysmal survival outcome. Our findings suggest that TT varies significantly between responders and non-responders. Duration of TT should be discussed with patients in shared decision-making when discussing palliative nivolumab.

查看原文本刊更多论文

纳武单抗在转移性头颈部鳞状细胞癌患者中的时间毒性：单一机构的经验。

背景：铂难治性复发和转移性头颈部鳞状细胞癌（r/mHNSCC）的治疗涉及免疫检查点抑制剂。时间毒性（TT）是一个新兴的指标与患者的生活质量和决策的影响。我们试图在这些患者中评估与纳武单抗相关的TT。方法：这是一项针对2018年1月1日至2022年12月31日期间在加拿大安大略省一个学术癌症中心就诊的铂难治性r/mHNSCC患者的回顾性单机构综述。主要指标是TT，定义为进行癌症相关活动的天数。结果：56例患者中位年龄为63岁（33-85岁），84%为男性。中位总生存期（OS）和3级免疫毒性分别为7.6个月和6.2%。中位TT为24天（1-109），占总OS的7.6%。在不良应答者中，TT占OS的14.9%。在存活超过一年的患者中，TT仅占4-6%。结论：我们的研究为TT提供了一个重要的、未被充分探索的以患者为中心的指标，特别是在无法治愈的、生存结果糟糕的HNSCC的背景下。我们的研究结果表明，TT在应答者和非应答者之间存在显著差异。在讨论姑息性纳武单抗时，应与患者共同讨论TT的持续时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.